Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (11601)	4/16/2003 10:25:37 AM
From: xcr600	Read Replies (1) \| Respond to of 48461

Yea I was going to post that to you.. Did it really hit $2.50 today? I missed that. Kind of lackluster now.

To: RockyBalboa who wrote (11601)	4/16/2003 11:04:42 AM
From: xcr600	Respond to of 48461

Maybe this is why it's trading lackluster-- BEIJING (Reuters) - A turnip a day keeps the SARS virus away, or so many in China's capital believe. Turnip prices have jumped in Beijing after the vegetable was touted as a key ingredient in a potion to fight the deadly virus that causes Severe Acute Respiratory Syndrome, peddlers said. -------------- I am out till tomorrow. WJ, enjoy your weather because it's terrible here. Snow in the forecast for us....

To: RockyBalboa who wrote (11601)	4/24/2003 12:26:42 PM
From: RockyBalboa	Read Replies (1) \| Respond to of 48461

CombiMatrix to Provide SARS Microarrays at No Cost to Key Research Centers Wednesday April 23, 8:03 am ET Toronto's Mt. Sinai Hospital First Group to Receive CombiMatrix SARS Microarrays Press Release Source: Acacia Research Corporation NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 23, 2003--Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) today announced that CombiMatrix will make its new SARS (Severe Acute Respiratory Syndrome) microarrays available to key government and academic researchers. "Due to the public health and economic implications of SARS, we have decided to offer a limited number of SARS microarrays at no cost to key research centers," said Dr. Amit Kumar, President and CEO of CombiMatrix. "I am amazed at how quickly CombiMatrix was able to prepare a custom microarray after the sequence was published," stated Dr. Chi Yip Ho, Director of the Microarray Laboratory of the Samuel Lunenfeld Research Institute at the Mt. Sinai Hospital in Toronto. "It is heartening to see the cooperation between commercial and academic centers on SARS. Mt. Sinai is one of the key centers treating cases of SARS in Toronto. I look forward to working with CombiMatrix and other researchers to enable a better understanding of the virus that will lead to new diagnostics and therapeutics." "The SARS Genome was published on April 14, 2003, and we were contacted by Dr. Ho the following day requesting information about our customizable microarray platform," Kumar said. "Dr. Ho's request prompted us to fabricate the first SARS microarrays for research use. These microarrays can be used in both basic and clinical research to support studies to understand the mechanism of infection and to potentially aid in the development of diagnostic tests, as well as therapeutics, against this disease." The CombiMatrix technology enables rapid content redesign and overnight synthesis of custom microarrays. The microarrays can also contain probes for genes in several host pathways. The CombiMatrix open platform allows researchers to use customized microarrays for their specific and immediate needs. About Acacia Research Corporation Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The Acacia Technologies group licenses its DMT and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications, from DNA synthesis/diagnostics to immunochemical detection. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. -------------------------------------------------------------------------------- Contact: Acacia Research Corporation, Newport Beach Bret L. Undem, 425/493-2293, Fax 425/493-2010